Literature DB >> 2753423

Concomitant radiation therapy and chemotherapy in the treatment of advanced squamous carcinoma of the lower female genital tract.

W S Roberts1, J J Kavanagh, H Greenberg, S C Bryson, J P LaPolla, P A Townsend, M S Hoffman, D Cavanagh, S Hewitt.   

Abstract

Twenty-three consecutive patients with advanced squamous carcinoma of the lower female genital tract were entered into a pilot study to determine the response rate and toxicity of a combination of intravenous cisplatin and 5-fluorouracil given concomitantly with radiation therapy. Twenty (87%) of the patients had a complete clinical response. Two patients (9%) had a partial response and one (4%) had stable disease. Nine (45%) of the complete responders have recurred with a median time to recurrence of 4 months. Seven (35%) had some component of local recurrence. The complete responders who have not recurred have been followed a median of 17 months. The acute toxicity was generally mild and there was no life-threatening acute complications. Three patients developed significant late complications. The response rate in this study was very high. The responses were usually prompt and dramatic, but often not sustained.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2753423     DOI: 10.1016/0090-8258(89)90138-8

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  3 in total

Review 1.  Concurrent chemotherapy and radiation therapy in primary cancer of the cervix.

Authors:  J M Schilder; F B Stehman
Journal:  Curr Oncol Rep       Date:  1999-09       Impact factor: 5.075

Review 2.  Chemotherapy of vulvar cancer: a review.

Authors:  Gunter Deppe; Ismail Mert; Jimmy Belotte; Ira S Winer
Journal:  Wien Klin Wochenschr       Date:  2013-03-22       Impact factor: 1.704

Review 3.  Chemoradiation for advanced primary vulval cancer.

Authors:  T S Shylasree; Andrew Bryant; Robert Ej Howells
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.